Mild hyperopia
Conditions
Interventions
Experimental group 2:Fit double-sided composite lenses
Control group:Prescription for single-vision lenses
Experimental group 1:Fit bifocal lenses with built-in diopter deviation
Sponsors
Bejing Tongren Hospital, Capital Medical Uniersity
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 6–14 years, any gender; 2. Refractive status meets the following criteria: (1) After cycloplegia, computerized refraction shows an equivalent spherical diopter in both eyes between 2.00D and 0D (inclusive); (2) After cycloplegia, computerized refraction shows astigmatism in both eyes = 1.0; 5. No amblyopia or other pathological changes in either eye; 6. Parents/guardians understand the plan and are willing to accept random group assignment; 7. The patient fully understands and voluntarily participates in this study, and both the patient and the parents/guardians have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Those who are allergic to the mydriatic agents used in this research (such as atropine, cyclopentolate, procaine, or benzalkonium chloride) or their components; 2.Either eye may have an abnormality of the refractive system, such as keratoconus, conical lens, spherical lens, etc. 3.Diseases that may affect the development of refractive errors or are prone to progressing to high myopia, such as: Down syndrome, Marfan syndrome, retinopathy of prematurity, neonatal hypoxic-ischemic encephalopathy patients, etc. 4.Either eye may have other ocular abnormalities or diseases that affect vision, such as ptosis of the upper eyelid, congenital abnormalities of the cornea, corneal leukoma, congenital lens abnormalities, cataract, macular degeneration, choroidal lesion, severe vitreous opacity, retinal lesion, etc. 5.Either eye has a history of glaucoma and/or has a shallow anterior chamber. 6.Previous or current conditions include obvious strabismus, amblyopia or nystagmus. 7.Those who have used drugs that may affect the evaluation of therapeutic effect within the past 3 months, either systemically or locally, are excluded. Such drugs include anticholinergic drugs such as atropine and pilocarpine; muscarinic drugs such as physostigmine; or drugs that may affect pupil size and accommodation, such as atropine tablets, morphine or sedative-hypnotic drugs. 8.Within one month, the following treatments for myopia control were used: atropine or other antimuscarinic drugs, bifocal/progressive or multifocal contact lenses, bifocal/progressive or multifocal frame glasses, orthokeratology lenses, rigid gas-permeable or other types of corneal contact lenses used to delay the progression of myopia. 9.History or current presence of systemic diseases: immune system disorders, central nervous system disorders, asthma, diabetes, severe cardiac or pulmonary dysfunction, severe liver or kidney dysfunction. 10.Unable to voluntarily participate in this study or having low enthusiasm; 11.Unable to cooperate with regular follow-ups and various examinations; 12.The researchers believe that there are any other circumstances that would disqualify one from participating in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fundus photography;Diopter;Axial length of the eye;Intraocular pressure;Slit lamp inspection; | — |
Countries
China
Contacts
Public ContactLei Tian
Bejing Tongren Hospital, Capital Medical Uniersity
Outcome results
None listed